How to use MICAFUNGINA ACCORDPHARMA 100 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet: Information for the User
Micafungina Accordpharma 50 mg powder for concentrate for solution for infusion EFG
Micafungina Accordpharma 100 mg powder for concentrate for solution for infusion EFG
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- If you experience any side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.
Contents of the pack
- What is Micafungina Accordpharma and what is it used for
- What you need to know before you use Micafungina Accordpharma
- How to use Micafungina Accordpharma
- Possible side effects
- Storage of Micafungina Accordpharma
- Contents of the pack and further information
1. What is Micafungina Accordpharma and what is it used for
Micafungina Accordpharma contains the active substance micafungin. Micafungin is an antifungal medicine used to treat infections caused by fungal cells.
Micafungin is used to treat fungal infections caused by fungal cells or yeasts called Candida. Micafungin is effective in treating systemic infections (those that have penetrated the body). It interferes with the production of a part of the fungal cell wall. The fungus needs an intact cell wall to live and grow. Micafungin causes defects in the fungal cell wall, preventing the fungus from growing and living.
When no other antifungal treatment is available, your doctor will prescribe micafungin in the following circumstances (see section 2):
- To treat a severe fungal infection in adults, adolescents, and children, including newborns, called invasive candidiasis (infection that has penetrated the body).
- To treat adults and adolescents ≥ 16 years old with a fungal infection in the throat (esophagus) where intravenous treatment is appropriate.
- To prevent Candida infection in patients undergoing bone marrow transplantation or who are expected to have neutropenia (low levels of neutrophils, a type of white blood cell) for 10 days or more.
2. What you need to know before you use Micafungina Accordpharma
Do not use Micafungina Accordpharma
- if you are allergic to micafungin, to other echinocandins (Ecalta or Cancidas), or to any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
In rats, long-term treatment with micafungin produced liver damage and subsequent liver tumors. The potential risk of developing liver tumors in humans is unknown; your doctor will advise you on the benefits and risks of treatment with micafungin before you start using it. Please inform your doctor if you have severe liver problems (e.g., liver failure or hepatitis) or if you have abnormal liver function tests. During treatment, your liver function will be monitored more closely. |
Talk to your doctor or pharmacist before starting micafungin
- if you are allergic to any medicine.
- if you have hemolytic anemia (anemia caused by the breakdown of red blood cells) or hemolysis (breakdown of red blood cells).
- if you have kidney problems (e.g., kidney failure or abnormal kidney function tests). In this case, your doctor may decide to monitor your kidney function more closely.
Micafungina can also cause severe skin and mucous membrane inflammation/eruption (Stevens-Johnson syndrome, toxic epidermal necrolysis).
Other medicines and micafungina
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
It is especially important that you tell your doctor if you are using amphotericin B desoxycholate or itraconazole (antifungal antibiotics), sirolimus (an immunosuppressant), or nifedipine (a calcium channel blocker used to treat high blood pressure). Your doctor may decide to adjust the dose of these medicines.
Using micafungina with food and drinks
Since micafungin is given by intravenous infusion (in a vein), there are no restrictions on food or drinks.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Micafungin should not be used during pregnancy unless clearly necessary. If you use micafungin, you should not breastfeed.
Driving and using machines
It is unlikely that micafungin will affect your ability to drive or use machines. However, some people may feel dizzy when taking this medicine, and if this happens to you, do not drive or use any machine or tool. Please inform your doctor if you experience any effect that may cause problems with driving or using machinery.
Micafungina Accordpharma contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose; this is essentially "sodium-free".
3. How to use Micafungina Accordpharma
Micafungina should be prepared and administered by a doctor or other healthcare professional. Micafungina should be given by slow intravenous infusion (in a vein) once a day. Your doctor will determine the dose of micafungin you will receive each day.
Use in adults, adolescents ≥ 16 years old, and elderly patients
- The usual dose for treating an invasive Candida infection is 100 mg per day for patients weighing more than 40 kg and 2 mg/kg per day for patients weighing 40 kg or less.
- The dose for treating an esophageal Candida infection is 150 mg for patients weighing more than 40 kg and 3 mg/kg per day for patients weighing 40 kg or less.
- The usual dose for preventing invasive Candida infections is 50 mg per day for patients weighing more than 40 kg and 1 mg/kg per day for patients weighing 40 kg or less.
Use in children ≥ 4 months old and adolescents < 16 years old
- The usual dose for treating an invasive Candida infection is 100 mg per day for patients weighing more than 40 kg and 2 mg/kg per day for patients weighing 40 kg or less.
- The usual dose for preventing invasive Candida infections is 50 mg per day for patients weighing more than 40 kg and 1 mg/kg per day for patients weighing 40 kg or less.
Use in children and infants < 4 months old
- The usual dose for treating an invasive Candida infection is 4-10 mg/kg per day.
- The usual dose for preventing invasive Candida infections is 2 mg/kg per day.
If you receive more micafungina than you should
Your doctor will monitor your response and the condition of your disease to determine the necessary dose of micafungin. However, if you are concerned that you have received too much micafungin, consult your doctor or another healthcare professional immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount received.
If you miss a dose of micafungina
Your doctor will monitor your response and the condition of your disease to determine the appropriate treatment with micafungin. However, if you are concerned that you have missed a dose of micafungina, contact your doctor or another healthcare professional immediately.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you suffer an allergic reaction or a severe skin reaction (e.g., blistering of the skin and peeling), you should inform your doctor or nurse immediately.
Micafungina can cause these other side effects:
Common (may affect up to 1 in 10 people)
- abnormal blood test results (reduction in the number of white blood cells [leukopenia; neutropenia]); reduction in the number of red blood cells (anemia)
- reduction of potassium in the blood (hypokalemia); reduction of magnesium in the blood (hypomagnesemia); reduction of calcium in the blood (hypocalcemia)
- headache
- inflammation in the vein wall (at the injection site)
- nausea (feeling sick); vomiting; diarrhea; abdominal pain
- abnormal liver function tests (increase in alkaline phosphatase; increase in aspartate aminotransferase; increase in alanine aminotransferase)
- increase in bilirubin in the blood (hyperbilirubinemia)
- rash
- fever
- chills
Uncommon (may affect up to 1 in 100 people)
- abnormal blood test results (reduction in the number of blood cells [pancytopenia]); reduction in the number of platelets (thrombocytopenia); increase in the number of a certain type of white blood cells called eosinophils; reduction of albumin in the blood (hypoalbuminemia)
- hypersensitivity
- increased sweating
- reduction of sodium in the blood (hyponatremia); increase of potassium in the blood (hyperkalemia); reduction of phosphates in the blood (hypophosphatemia); anorexia (eating disorder)
- insomnia (difficulty sleeping); anxiety; confusion
- drowsiness (somnolence); tremors; dizziness; alteration of taste
- increased heart rate; stronger heartbeat; irregular heartbeat
- high or low blood pressure; flushing
- shortness of breath
- indigestion; constipation
- liver failure; increase in liver enzymes (gamma-glutamyltransferase); jaundice (yellowing of the skin or the white part of the eyes due to liver or blood problems); reduction of bile reaching the intestine (cholestasis); increase in liver size; liver inflammation
- rash with itching (urticaria); itching; flushing (erythema)
- abnormal kidney function tests (increase in creatinine in the blood; increase in urea in the blood); worsening of kidney failure
- increase in an enzyme called lactate dehydrogenase
- clot formation at the injection site; inflammation at the injection site; pain at the injection site; fluid accumulation in the body
Rare (may affect up to 1 in 1,000 people)
- anemia caused by the breakdown of red blood cells (hemolytic anemia), breakdown of red blood cells (hemolysis)
Not known (frequency cannot be estimated from the available data)
- blood coagulation disorders
- shock (allergic)
- liver cell damage including death
- kidney problems; acute kidney failure
Other side effects in children and adolescents
The following reactions have been described more frequently in pediatric patients than in adults:
Common (may affect up to 1 in 10 people)
- reduction of platelets in the blood (thrombocytopenia)
- increased heart rate (tachycardia)
- high or low blood pressure
- increase in bilirubin in the blood (hyperbilirubinemia); increase in liver size
- acute kidney failure; increase in urea in the blood
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Monitoring System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of Micafungina Accordpharma
Keep this medicine out of the sight and reach of children.
Do not use micafungina after the expiry date which is stated on the vial and on the carton (EXP). The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions.
Keep the vial in the outer packaging to protect it from light.
Reconstituted concentrate in the vial
The chemical and physical stability of the product has been demonstrated for 48 hours at 2-8°C and at 20-25°C, when reconstituted with sodium chloride 9 mg/ml (0.9%) solution for infusion or with glucose 50 mg/ml (5%) solution for infusion.
Diluted solution for infusion
The chemical and physical stability that allows its use has been demonstrated for 96 hours at 2-8°C and at 20-25°C, protected from light, when diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion or with glucose 50 mg/ml (5%) solution for infusion.
Micafungina does not contain preservatives. From a microbiological point of view, the diluted and reconstituted solutions should be used immediately. If not used immediately, the times and conditions of storage prior to use are the responsibility of the user and should not exceed 24 hours at a temperature between 2 and 8°C, unless the reconstitution and dilution have been carried out under controlled and validated aseptic conditions.
Do not use the diluted solution for infusion if you notice it is cloudy or if a precipitate has formed.
To protect the bottle/bag containing the diluted solution for infusion from light, it should be placed in an opaque bag with a seal.
The vial is for single use only. Therefore, any unused reconstituted concentrate should be discarded immediately.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
6. Container Contents and Additional Information
Composition of Micafungina Accordpharma
- The active ingredient is micafungin (as sodium salt).
1 vial contains 50 mg or 100 mg of micafungin (as sodium salt).
- The other components are lactose monohydrate, citric acid, and sodium hydroxide.
Appearance of the Product and Container Contents
Micafungina Accordpharma is supplied as a white lyophilized powder in a glass vial with a rubber stopper and an aluminum seal. Each vial contains 50 mg or 100 mg of micafungin (as sodium salt).
Each container contains 1 vial.
Marketing Authorization Holder
Accord Healthcare, S.L.U.
World Trade Center
Moll de Barcelona, s/n.
Edifici Est 6ª planta 08039 - Barcelona
Spain
Manufacturer
Accord Healthcare Polska Sp.z o.o.
ul. Lutomierska 50,
95-200 Pabianice, Poland
or
Laboratori Fundació Dau
C/ C, 12-14 Pol. Ind.
Zona Franca, Barcelona, 08040,
Spain
This Medicinal Product is Authorized in the EEA Member States Under the Following Names:
Member State | Medicinal Product Name |
Cyprus | Micafungin Accord 50 mg powder for concentrate for solution for infusion Micafungin Accord 100 mg powder for concentrate for solution for infusion |
Czech Republic | Mikafungin Accord |
Croatia | Mikafungin Accord 50 mg powder for concentrate for solution for infusion Mikafungin Accord 100 mg powder for concentrate for solution for infusion |
Finland | Micafungin Accord 50 mg dry substance for concentrate for solution for infusion, solution Micafungin Accord 100 mg dry substance for concentrate for solution for infusion, solution |
France | Micafungine Accord 50 mg powder for solution to be diluted for perfusion Micafungine Accord 100 mg powder for solution to be diluted for perfusion |
Hungary | Mikafungin 50 mg powder for concentrate for infusion solution Mikafungin 100 mg powder for concentrate for infusion solution |
Italy | Micafungin Accord 50 mg Micafungin Accord 100 mg |
Latvia | Micafungin Accord 100 mg powder for concentrate for infusion solution preparation |
Lithuania | Micafungin Accord 100 mg powder for infusion solution concentrate |
Netherlands | Micafungine Accord 50 mg powder for concentrate for solution for infusion Micafungine Accord 100 mg powder for concentrate for solution for infusion |
Norway | Micafungin Accord 50 mg Micafungin Accord 100 mg |
Poland | Mikafungina Accordpharma 50 mg Mikafungina Accordpharma 100 mg |
Portugal | Micafungina Accordpharma 50 mg Micafungina Accordpharma 100 mg |
Slovenia | Mikafungina 50 mg powder for concentrate for solution for infusion Mikafungina 100 mg powder for concentrate for solution for infusion |
Slovakia | Mikafungín Accord 100 mg powder for infusion solution concentrate |
Sweden | Micafungin Accord 50 mg powder for concentrate for infusion solution, solution Micafungin Accord 100 mg powder for concentrate for infusion solution, solution |
Date of the Last Revision of this Leaflet:May 2025
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
This information is intended only for healthcare professionals:
Micafungin should not be mixed or infused simultaneously with other medicinal products except those mentioned below. Micafungin is reconstituted and diluted using aseptic techniques at room temperature, as follows:
- The plastic cap should be removed from the vial and the rubber stopper should be disinfected with alcohol.
- 5 ml of sodium chloride 9 mg/ml (0.9%) solution for perfusion or glucose 50 mg/ml (5%) solution for infusion (taken from a 100 ml bottle/bag) should be slowly and aseptically injected into each vial along the inner wall. Although the concentrate will foam, care should be taken to minimize the amount of foam generated. A sufficient number of micafungin vials should be reconstituted to obtain the required dose in mg (see the table below).
- The vial should be gently rotated. IT SHOULD NOT BE SHAKEN. The powder will dissolve completely. The concentrate should be used immediately. The vial is for single use. Therefore, any unused reconstituted concentrate should be discarded immediately.
- All the reconstituted concentrate should be removed from each vial and returned to the bottle/bag for perfusion from which it was initially taken. The diluted solution for perfusion should be used immediately. It has been demonstrated that the chemical and physical stability allows the use of the medicinal product for 96 hours, when stored at 25°C, provided it is protected from light, and the dilution is performed as described above.
- The bottle/bag for perfusion should be carefully inverted to disperse the diluted solution but SHOULD NOT BE SHAKEN, to avoid foam formation. The solution should not be used if it is turbid or if a precipitate has formed.
- The bottle/bag containing the diluted solution for perfusion should be placed in an opaque bag with a seal to protect it from light.
- Only clear and practically particle-free solutions should be used.
Preparation of the Solution for Perfusion
Dose (mg) | Micafungin Vial to be Used (mg/vial) | Volume of Sodium Chloride (0.9%) or Glucose (5%) to be Added to Each Vial | Volume (Concentration) of Reconstituted Powder | Standard Perfusion (up to 100 ml) Final Concentration |
50 | 1 x 50 | 5 ml | approx. 5 ml (10 mg/ml) | 0.5 mg/ml |
100 | 1 x 100 | 5 ml | approx. 5 ml (20 mg/ml) | 1.0 mg/ml |
150 | 1 x 100 + 1 x 50 | 5 ml | approx. 10 ml | 1.5 mg/ml |
200 | 2 x 100 | 5 ml | approx. 10 ml | 2.0 mg/ml |
- Country of registration
- Dosage formINJECTABLE PERFUSION, 100 mg
- ATC codeJ02AX05
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to MICAFUNGINA ACCORDPHARMA 100 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTIONDosage form: INJECTABLE PERFUSION, 100 mgActive substance: micafunginManufacturer: Accord Healthcare S.L.U.Prescription requiredDosage form: INJECTABLE PERFUSION, 50 mgActive substance: micafunginManufacturer: Accord Healthcare S.L.U.Prescription requiredDosage form: INJECTABLE PERFUSION, 50 mgActive substance: micafunginManufacturer: Accord Healthcare S.L.U.Prescription required
Online doctors for MICAFUNGINA ACCORDPHARMA 100 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION
Discuss questions about MICAFUNGINA ACCORDPHARMA 100 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Get MICAFUNGINA ACCORDPHARMA 100 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION Prescription Online
Fill in a 2-min form
Tell us your symptoms, history, and what medicine you're requesting.
Pick a doctor or let us assign
Choose a specialist or we'll match you with the next available doctor.
Doctor reviews your case
Usually within 30 minutes. They may ask follow-up questions via chat.
Collect from any pharmacy
Electronic prescription sent to your email — valid across Spain.
Frequently Asked Questions
MICAFUNGINA ACCORDPHARMA 100 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
The active ingredient in MICAFUNGINA ACCORDPHARMA 100 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION is micafungin. This information helps identify medicines with the same composition but different brand names.
MICAFUNGINA ACCORDPHARMA 100 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION is manufactured by Accord Healthcare S.L.U.. Pharmacy brands and packaging may differ depending on the distributor.
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether MICAFUNGINA ACCORDPHARMA 100 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
Spain has a well-developed healthcare infrastructure across major cities such as Madrid, Barcelona, Valencia, and Seville. Pharmacies are widely available and operate under strict regulations, ensuring access to prescribed medications.
You can buy MICAFUNGINA ACCORDPHARMA 100 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION in Madrid, Barcelona, Seville, or Valencia at any local pharmacy with a valid prescription.
To obtain a prescription, you can use Oladoctor:
Other medicines with the same active substance (micafungin) include MICAFUNGINA ACCORD 100 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION, MICAFUNGINA ACCORD 50 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION, MICAFUNGINA ACCORDPHARMA 50 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
